GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Days Inventory

AVBP (ArriVent BioPharma) Days Inventory : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). ArriVent BioPharma's Average Total Inventories for the three months ended in Dec. 2024 was $0.00 Mil. ArriVent BioPharma's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for ArriVent BioPharma's Days Inventory or its related term are showing as below:

AVBP's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 177.045
* Ranked among companies with meaningful Days Inventory only.

ArriVent BioPharma's Days Inventory stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


ArriVent BioPharma Days Inventory Historical Data

The historical data trend for ArriVent BioPharma's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Days Inventory Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Days Inventory
- - - -

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ArriVent BioPharma's Days Inventory

For the Biotechnology subindustry, ArriVent BioPharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArriVent BioPharma's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Days Inventory distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Days Inventory falls into.


;
;

ArriVent BioPharma Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ArriVent BioPharma's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as

Days Inventory (A: Dec. 2024 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

ArriVent BioPharma's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:

Days Inventory (Q: Dec. 2024 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2024 ) + Total Inventories (Q: Dec. 2024 )) / count ) / Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ArriVent BioPharma  (NAS:AVBP) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

ArriVent BioPharma's Inventory Turnover for the three months ended in Dec. 2024 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ArriVent BioPharma's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


ArriVent BioPharma Days Inventory Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma Business Description

Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.